遗传性血管性水肿:长期康力龙治疗的安全性。

文章的细节

引用

复制到剪贴板

斯隆德,李CW, Sheffer

遗传性血管性水肿:长期康力龙治疗的安全性。

J过敏Immunol。2007年9月,120 (3):654 - 8。

PubMed ID

17765757 (在PubMed

]

文摘

背景:减毒雄激素控制遗传性血管性水肿的攻击。短期研究的患者在我们的机构与减毒雄激素证明没有不利影响。然而,患者接受长期治疗的副作用频率是相对较少的特点。目的:评估的频率衰减的各种副作用雄激素康力龙治疗遗传性血管性水肿患者的人口20到40年。方法:数据副作用的患者继续康力龙治疗取得了自1987年以来通过问卷。患者通过体格检查评估;生化检测肝脏功能、血清脂质和前列腺特异性抗原;和肝脏超声检查。结果:康力龙的最小初始有效剂量是0.5到2.0毫克每日,尽管大多数患者症状达到控制和减少剂量和频率作为攻击的频率降低了。在十21患者治疗相关症状的发展。 No interruption in stanozolol therapy was required because symptoms subsided with a reduction in the stanozolol dosage. Adverse side effects included hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne, and mood changes. Liver enzyme assays revealed no persistent abnormalities. Liver ultrasounds in 8 patients revealed 3 abnormalities deemed unrelated to therapy. Five patients had a reduced high-density lipoprotein, and 2 patients had elevated triglycerides. CONCLUSION: Stanozolol is a safe and effective drug for the long-term management of hereditary angioedema. CLINICAL IMPLICATIONS: Stanozolol may be used in the long-term treatment of patients with hereditary angioedema provided such patients are closely supervised with routine clinical, biochemical, and radiologic assessments.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

康力龙